Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07645391 · ClinicalTrials.gov registry record
Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- 200
- Enrollment target
NCT07645391: Recruiting study, sponsored by University of Michigan Rogel Cancer Center.
NCT07645391 is a clinical trial that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07645391 is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
Study Summary
This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.
Primary Outcome
Descriptive statistics, parametric and non-parametric statistical tests will be used to summarize the clinical variables. Will estimate the prevalence and incidence. Will fit two statistical models with cross-validation to evaluate the performance characteristics (Brier score, area under curve, sensitivity, specificity, positive and negative predictive values) of SelectMDx in predicting i) HG PCa and ii) any PCa.
Interventions
- OTHER Non-Interventional Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2030-01 |
What NCT07645391 shows while recruiting
NCT07645391 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT07645391 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07645391 about?
NCT07645391 is a clinical study titled "Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer". This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.
What is the current status of trial NCT07645391?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2017-01-01. Estimated completion is 2030-01.
What interventions are being tested in trial NCT07645391?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT07645391?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI